Response to comment on ‘Drug‐releasing intravesical floating technology for sequential gemcitabine and docetaxel in non‐muscle‐invasive bladder cancer’

Documenti analoghi

• Drug‐releasing intravesical floating technology for sequential gemcitabine and docetaxel in non‐muscle‐invasive bladder cancer
  di: Ashley C. Rhodes, et al.
  Pubblicazione: (2025)
• Quality of life and cost‐effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG ‐naïve non‐muscle‐invasive bladder cancer
  di: Aviral Srivastava, et al.
  Pubblicazione: (2025)
• Prognostic role of the neutrophil/lymphocyte ratio in high‐risk BCG‐naïve non‐muscle‐invasive bladder cancer treated with intravesical gemcitabine/docetaxel
  di: Mohamad Abou Chakra, et al.
  Pubblicazione: (2024)
• Computed tomography ‐derived extracellular volume fraction is associated with high‐grade recurrence in non‐muscle‐invasive bladder cancer treated with intravesical gemcitabine and docetaxel
  di: Mohamad Abou Chakra, et al.
  Pubblicazione: (2026)
• Adjuvant intravesical therapy in intermediate‐risk non‐muscle‐invasive bladder cancer
  di: Ekaterina Laukhtina, et al.
  Pubblicazione: (2024)